Cardioprotection by long-term ETA receptor blockade and ACE inhibition in rats with congestive heart failure: Mono- versus combination therapy

Cardiovascular Research

Volumn 54, Issue 1, 2002, Pages 85-94

  Fraccarollo, Daniela ^a   Bauersachs, Johann ^a   Kellner, Markus ^a   Galuppo, Paolo ^a   Ertl, Georg ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Angiotensin; Endothelins; Fibrosis; Heart failure; Infarction

Indexed keywords

ALPHA ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; MESSENGER RNA; MYOSIN; TRANDOLAPRIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DOSE TIME EFFECT RELATION; GENE EXPRESSION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; ZYMOGRAPHY;

EID: 0036220503     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00553-3     Document Type: Article

References (50)

1. Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation
2. Structural basis of end-stage failure in ischemic cardiomyopathy in humans
3. Cardiac remodeling - Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling
4. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy
5. A remarkable medical story: Benefits of angiotensin-converting enzyme inhibitors in cardiac patients
6. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases
7. Influence of chronic captopril therapy on the infarcted left ventricle of the rat
8. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat
9. Increased plasma concentrations of endothelin in congestive heart failure in humans
10. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
11. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: Possible involvement of myocardial endothelin system in ventricular remodeling
12. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure
13. Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure
14. Endothelin receptor antagonists in congestive heart failure: A new therapeutic principle for the future?
15. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction
16. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist
17. Determination of hydroxyproline
18. Alteration of collagen phenotypes in ischemic cardiomyopathy
19. Regulation of collagen degradation in the rat myocardium after infarction
20. Quantitative zymography: Detection of picogram quantities of gelatinases
21. Quantitative reverse zymography: Analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms
22. Myocardial infarct size and ventricular function in rats
23. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan)
24. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors
25. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
26. Endothelin receptor antagonism in patients with chronic heart failure
27. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure
28. Effects of endothelins on collagen turnover in cardiac fibroblasts
29. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin
30. Myocardial fibrosis in DOCA-salt hypertensive rats: Effect of endothelin ET(A) receptor antagonism
31. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat
32. Myocardial matrix degradation and metalloproteinase activation in the failing heart: A potential therapeutic target
33. Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation
34. The molecular biology of heart failure
35. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats
36. Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure
37. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium
38. Myosin heavy chain isoform expression in the failing and nonfailing human heart
39. Alterations of cross-bridge kinetics in human atrial and ventricular myocardium
40. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes
41. Cardiac endothelin system impairs left ventricular function in renin-dependent hypertension via decreased sarcoplasmic reticulum Ca(2+) uptake
42. Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model
43. Endothelin-receptor blockade improves endothelial vasomotor dysfunction in heart failure
44. Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: Effects on left ventricular performance
45. Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure
46. Plasma endothelin in congestive heart failure: Effect of the ACE inhibitor, fosinopril
47. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure
48. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
49. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure
50. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure